Trial
NCT05014139
A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Astellas Pharma Global Development, Inc.
Collaborators
Seagen, a wholly owned subsidiary of Pfizer
Condition
Urinary Bladder Neoplasms
Intervention
Enfortumab vedotin
Why stopped
Trial was discontinued for strategic reasons. Decision was not based on safety concerns, futility, or request from regulatory authority, ethics committee, or institutional review board or EC/IRB.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-11-20